Please login to the form below

Delivering on what matters to patients

Patients are assets to the solution-making process, but to leverage their ... need to be ready to listen and observe what matters to patients.

In the book, ‘The Disney Way: Harnessing the Management Secrets of Disney in Your Company,’ authors Bill Capodagli and Lynn Jackson reveal how Disney consistently delivers a level of customer service that exceeds the customer’s expectations each time. As an example, the authors share a story about Disney hotel staff members who discreetly placed large stuffed character animals inside the hotel room of a young family who were guests at the hotel. The stuffed animals “mysteriously” changed their positions every time the family returned to the room, much to the entertainment and wonder of the children and to the delight of the parents.

This kind of service goes above and beyond, creating an experience that customers will forever talk about. The company’s brand of customer service targets what truly matters to customers. It is so deeply embedded within the company culture that it has come to be known as “The Disney Way” – and it is something every company should strive for, including those in the healthcare and biopharmaceutical industries.


What matters to patients

According to Emma Sutcliffe, Patient Engagement and Socialised Health Expert, the essential question asked by patients, and that companies need to measure themselves against, is: “Are you there when I need you?” In other words, are biopharma companies really present in ways that truly matter to patients and in places where patients want them to be? 

If the statement “Not everything that matters can be measured, and not everything that can be measured matters” is true, then biopharma need to quickly find a way of understanding what matters. Knowing what really matters, especially to patients, could be a huge differentiator.

But what does matter to patients? And how can the industry find out what really matters to them?  Not surprisingly, the simple answer is listening to patients, as opposed to trying to manage them and making decisions on their behalf. Conducting workshops that serve as a venue for patients to discuss their challenges, needs and ideas is a good place to start. Conversations with patients can generate multiple insights and enable a community-first approach to developing solutions, where patients act as co-creators in the design process. 

Essentially, the approach to patients should be human-centric, rather than disease-centric. Knowing what matters to patients is going beyond what is clinically needed to target a disease, and moving towards developing therapeutic services that are overall solutions to improved living.


Assessing a subjective area

What matters to people often involves emotion, sentiment and personal opinion. These concepts can be perplexing to companies, who are dependent on using objective methods of evaluation. So, how can an area as subjective as “what matters to patients” be measured and authentically assessed?

Before anything else, biopharma companies must evaluate the current business models and metrics they adopt in order to determine whether they give consideration to the subjective aspect of the patient experience. Furthermore, they must identify at which patient journey points they can “meet” the patient. By studying the journey of the patient, companies will begin to realise that there are a number of opportunities to improve customer engagement, and to “be there” for patients. Here are four measurable areas that matter to patients:
  • Quality, timeliness and relevance of content and educational resources. Availability of information and educational resources is an important measure of being there for patients. During the initial stages of their health journey, patients often overflow with curiosity and ask a million questions about a condition that they have or suspect they have. Sharing health information at the point of awareness, when patients seek to know more, is a crucial form of support for them.
  • Patient access. Are patients happy to take their medicine? Are doctors, family members and caregivers supportive of them taking a particular drug? Companies need to answer these kinds of questions and measure the success of a product based on whether it has reached the hands of the patient and that the patient is consistently taking it based on the right dosage. Health outcomes can only be realised if patients take their medicines.
To read the rest of this post, visit: http://www.wearecouch.com/blog/what-matters-to-patients

10th March 2017

Share

Tags

Company Details

COUCH.

+44 (0) 161 818 8399

Contact Website

Address:
4th Floor, Churchgate House
56, Oxford Street
Manchester
M1 6EU
United Kingdom

Latest content on this profile

Improving medication adherence by increasing health literacy
Health literacy and therapy adherence are interlinked. Improving health literacy involves removing barriers that prevent patients’ medical understanding.
COUCH.
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives.
COUCH.
Health knowledge: Why is it so important?
Health knowledge plays an important role in population health, but by itself is rarely enough to prompt a change in the behaviours that cause the risks.
COUCH.
COUCH study finds almost half of patients skip medication
Young people and less educated among those with less understanding of their health condition, according to UK-wide survey
COUCH.
Does a lack of understanding of human behaviour affect healthcare?
Only by synthesising research across multiple disciplines can we truly understand how to effect patient behaviour change
COUCH.
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement.
COUCH.